{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:28:41Z","timestamp":1790303321503,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2020\/133\/Startup\/08"],"award-info":[{"award-number":["NUHSRO\/2020\/133\/Startup\/08"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00259-025-07245-8","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T02:41:16Z","timestamp":1744252876000},"page":"4033-4043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PSMA-targeted radioligand therapy with [177Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study"],"prefix":"10.1007","volume":"52","author":[{"given":"Lu","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0870","authenticated-orcid":false,"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"7245_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209:1082\u201390.","journal-title":"J Urol"},{"key":"7245_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and united States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584\u201390.","journal-title":"Chin Med J"},{"key":"7245_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","volume":"5","author":"A Davies","year":"2019","unstructured":"Davies A, Conteduca V, Zoubeidi A, Beltran H. Biological evolution of Castration-resistant prostate cancer. Eur Urol Focus. 2019;5:147\u201354.","journal-title":"Eur Urol Focus"},{"key":"7245_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA approval summary: lutetium Lu 177 Vipivotide tetraxetan for patients with metastatic Castration-Resistant prostate cancer. Clin cancer Research: Official J Am Association Cancer Res. 2023;29:1651\u20137.","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"key":"7245_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet (London England). 2021;397:797\u2013804.","journal-title":"Lancet (London England)"},{"key":"7245_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7245_CR7","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-Labeled prostate-Specific membrane antigen radioligand therapy of metastatic Castration-Resistant prostate cancer: safety and efficacy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2016;57:1006\u201313.","journal-title":"Soc Nuclear Med"},{"key":"7245_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.2967\/jnumed.123.266741","volume":"65","author":"A Dierks","year":"2024","unstructured":"Dierks A, G\u00e4ble A, Rinscheid A, Wienand G, Pfob CH, Kircher M, et al. First safety and efficacy data with the radiohybrid (177)Lu-rhPSMA-10.1 for the treatment of metastatic prostate cancer. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2024;65:432\u20137.","journal-title":"Soc Nuclear Med"},{"key":"7245_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/RLU.0000000000003925","volume":"46","author":"Y Sanli","year":"2021","unstructured":"Sanli Y, Kuyumcu S, Simsek DH, B\u00fcy\u00fckkaya F, Civan C, Isik EG, et al. 225Ac-Prostate-Specific membrane antigen therapy for Castration-Resistant prostate cancer: A Single-Center experience. Clin Nucl Med. 2021;46:943\u201351.","journal-title":"Clin Nucl Med"},{"key":"7245_CR10","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, et al. Development of [(177)Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023;50:2846\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7245_CR11","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","volume":"29","author":"Z Wang","year":"2018","unstructured":"Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single Low-Dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates Prostate-Specific membrane antigen positive tumors. Bioconjug Chem. 2018;29:3213\u201321.","journal-title":"Bioconjug Chem"},{"key":"7245_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of (177)Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7245_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","volume":"51","author":"J Zang","year":"2024","unstructured":"Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [(177)Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:871\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7245_CR14","unstructured":"Wang J, Wang R, Zhao T, Zhu Z, Chen X, Zhang J, Safety. Maximum tolerated dose, and patient-specific dosimetry of [177Lu]Lu-LNC1011 in metastatic Castration-Resistant prostate cancer patients. J Nucl Med. 2024:242391."},{"key":"7245_CR15","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E. OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med Off Publ Soc Nuclear Med. 2005;46:1023\u20137.","journal-title":"Soc Nuclear Med"},{"key":"7245_CR16","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36:1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7245_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for Castration-Resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncology: Official J Am Soc Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"7245_CR18","doi-asserted-by":"publisher","first-page":"s122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2009;50(Suppl 1):s122\u201350.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"7245_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [(68)Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [(177)Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49:1584\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7245_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic Castration-Resistant prostate cancer: correlations between pretherapeutic imaging and Whole-Body tumor dosimetry with treatment outcomes. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2019;60:517\u201323.","journal-title":"Soc Nuclear Med"},{"key":"7245_CR21","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, M\u00fcller D, Baum RP. Prostate-Specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic Castration-Resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:1199\u2013207.","journal-title":"Soc Nuclear Med"},{"key":"7245_CR22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1039\/C5CS00158G","volume":"45","author":"Z Liu","year":"2016","unstructured":"Liu Z, Chen X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev. 2016;45:1432\u201356.","journal-title":"Chem Soc Rev"},{"key":"7245_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7150\/thno.23491","volume":"8","author":"R Tian","year":"2018","unstructured":"Tian R, Jacobson O, Niu G, Kiesewetter DO, Wang Z, Zhu G, et al. Evans blue attachment enhances somatostatin receptor Subtype-2 imaging and radiotherapy. Theranostics. 2018;8:735\u201345.","journal-title":"Theranostics"},{"key":"7245_CR24","doi-asserted-by":"crossref","unstructured":"von Eyben FE, Bauman G, von Eyben R, Rahbar K, Soydal C, Haug AR et al. Optimizing PSMA radioligand therapy for patients with metastatic Castration-Resistant prostate cancer. A systematic review and Meta-Analysis. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21239054"},{"key":"7245_CR25","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.7150\/thno.44568","volume":"10","author":"FE von Eyben","year":"2020","unstructured":"von Eyben FE, Kulkarni HR, Baum RP. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy. Theranostics. 2020;10:4900\u20132.","journal-title":"Theranostics"},{"key":"7245_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325\u201334.","journal-title":"Eur Urol"},{"key":"7245_CR27","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1097\/RLU.0000000000003912","volume":"47","author":"S Usmani","year":"2022","unstructured":"Usmani S, Al Kandari F, Alrekhais I, Ahmed SNK. Excellent response to adapted Low-Dose 177Lu-PSMA-617 PSMA therapy in renal compromise patient. Clin Nucl Med. 2022;47:e213\u20134.","journal-title":"Clin Nucl Med"},{"key":"7245_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, et al. Long-Term nephrotoxicity of 177Lu-PSMA radioligand therapy. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2024;65:79\u201384.","journal-title":"Soc Nuclear Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07245-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07245-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:51:23Z","timestamp":1757155883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07245-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7245"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07245-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Jiangnan University (LS2023048, Clinical trial number: not applicable). The study involving human participants adhered to the principles of the Ethics Committee of the Affiliated Hospital of Jiangnan University and the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing financial interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}